Evidence map›Paper›PMID 29596120›Full record

ArticleAnnals of surgery2019

Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection.

Georgios Gemenetzis, Vincent P Groot, Alex B Blair, Daniel A Laheru, Lei Zheng, Amol K Narang, Elliot K Fishman, Ralph H Hruban, Jun Yu, Richard A Burkhart and 4 more

2 registry-linked trialsAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of surgery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 193 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
193citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04289792 phase2unknown statusnot on this mapstarted 2020, after this paper: background citation

Chemotherapy-based Split Stereotactic Body Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: Study Protocol of a Prospective, Single-arm Phase II Trial

TypeinterventionalSponsorFujian Medical University Union HospitalRan2020 to 2025Enrolled27ConditionsPancreatic NeoplasmsArmsnab-Paclitaxel+Gemcitabine, split-course SBRT
NCT05400681 unknown statusnot on this mapstarted 2020, after this paper: background citation

Pre- and Postoperative Incidence and Prognostic Implication of Positive Peritoneal Lavage and Circulating Tumor DNA in Patients With Pancreatic Cancer

Typeobservational_patient_registrySponsorSonke DetlefsenRan2020 to 2024Enrolled200ConditionsPancreatic Cancer, Pancreatic Adenocarcinoma
3 · Its place in the literature

Who cites it

193 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Article
  15. Observational
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

133 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Georgios GemenetzisDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD.
Vincent P GrootDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD.
Alex B BlairDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD.
Daniel A LaheruDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD.
Lei ZhengDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD.
Amol K NarangDepartment of Radiation Oncology, Johns Hopkins University School of Medicine, Baltimore, MD.
Elliot K FishmanDepartment of Radiology, Johns Hopkins University School of Medicine, Baltimore, MD.
Ralph H HrubanDepartment of Pathology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, MD.
Jun YuDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD.
Richard A BurkhartDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD.
John L CameronDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD.
Matthew J WeissDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD.
Christopher L WolfgangDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD.
Jin HeDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD.

Funding

Tumor Antigens for Individual Signatures and TherapyP50CA062924 · NCI · JOHNS HOPKINS UNIVERSITY · PI LENNON, ANNE MARIE · 1993 to 2022
$54.6M
Clinical and Laboratory Research Training for Surgical OncologistsT32CA126607 · NCI · JOHNS HOPKINS UNIVERSITY · PI CAMERON, ANDREW M. · 2008 to 2024
$6.0M
Targeting the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer with a Neoadjuvant Platform Clinical TrialR01CA197296 · NCI · JOHNS HOPKINS UNIVERSITY · PI William Reece Burns, Eric Christenson · 2015 to 2026
$5.7M
NCI NIH HHS P50 CA062924NCI NIH HHS R01 CA197296NCI NIH HHS T32 CA126607
6 · The paper itself

Abstract

objectiveThe aim of the study was to identify the survival of patients with locally advanced pancreatic cancer (LAPC) and assess the effect of surgical resection after neoadjuvant therapy on patient outcomes.

backgroundAn increasing number of LAPC patients who respond favorably to neoadjuvant therapy undergo surgical resection. The impact of surgery on patient survival is largely unknown. MATERIALS AND

methodsAll LAPC patients who presented to the institutional pancreatic multidisciplinary clinic (PMDC) from January 2013 to September 2017 were included in the study. Demographics and clinical data on neoadjuvant treatment and surgical resection were documented. Primary tumor resection rates after neoadjuvant therapy and overall survival (OS) were the primary study endpoints.

resultsA total of 415 LAPC patients were included in the study. Stratification of neoadjuvant therapy in FOLFIRINOX-based, gemcitabine-based, and combination of the two, and subsequent outcome comparison did not demonstrate significant differences in OS of 331 non-resected LAPC patients (P = 0.134). Eighty-four patients underwent resection of the primary tumor (20%), after a median duration of 5 months of neoadjuvant therapy. FOLFIRINOX-based therapy and stereotactic body radiation therapy correlated with increased probability of resection (P = 0.006). Resected patients had better performance status, smaller median tumor size (P = 0.029), and lower median CA19-9 values (P < 0.001) at PMDC. Patients who underwent surgical resection had significant higher median OS compared with those who did not (35.3 vs 16.3 mo, P < 0.001). The difference remained significant when non-resected patients were matched for time of neoadjuvant therapy (19.9 mo, P < 0.001).

conclusionsSurgical resection of LAPC after neoadjuvant therapy is feasible in a highly selected cohort of patients (20%) and is associated with significantly longer median overall survival.

Indexed as

Neoplasm StagingAgedAntimetabolites, AntineoplasticDeoxycytidineFemaleFollow-Up StudiesGemcitabineHumansMaleMiddle AgedNeoadjuvant TherapyPancreatectomyPancreatic NeoplasmsRetrospective StudiesSurvival RateUnited StatesAntimetabolites, AntineoplasticDeoxycytidineGemcitabine

Identifiers

PMID29596120
PMCPMC6985003

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.